The human T-cell leukemia retrovirus type-1 (HTLV-1) p30
The HTLV-1 is a complex oncoretrovirus that infects CD4 þ T-lymphocytes and causes adult T-cell leukemia/lymphoma (ATLL) -an aggressive and often fatal hematological malignancy that is resistant to most anticancer treatments (Johnson et al., 2001; Kannian and Green., 2010; Giam and Jeang., 2007) . Similar to other transforming viruses, such as Epstein-Barr virus (EBV), hepatitis B and C viruses (HBV and HCV), human papillomavirus (HPV), and Kaposi sarcoma herpesvirus/human herpesvirus-8 (KSHV/HHV-8), the HTLV-1 induces viral latency associated with the establishment of persistent long-term infections which can lead to the development of malignant disease (Lairmore et al., 2011 Jeang, 2011; Cesarman and Mesri, 2007; Chen et al., 2013) . Importantly, the mechanisms by which HTLV-1 deregulates host signaling pathways and gene expression to promote aberrant T-cell lymphoproliferation are not yet completely defined. The HTLV-1 provirus encodes at least seven regulatory/nonstructural and accessory proteins (Tax, Rex, p8 (Koralnik et al., 1993; Nicot et al., 2005; Cereseto et al., 1997; Edwards et al., 2011; Silic-Benussi et al., 2010; Bai and Nicot, 2012; Van Prooyen et al., 2010; Ma et al., 2013; Arnold et al., 2006) . The Tax transactivator protein interacts with cellular transcription factors (CREB/ATF-1, and SRF p67 , p300/CREB-binding protein and the p300/CBP-associated factor) and regulates the expression of proviral and cellular genes Tang et al., 1998; ; Nicot and Harrod, 2000; Currer et al., 2012; Ho et al., 2012; Zhao and Giam, 1992; Georges et al., 2003; Wu and Sun, 2007; Zane et al., 2012) . While Tax is generally considered to be the major oncoprotein of HTLV-1 involved in early Tcell immortalization and leukemic transformation, the HTLV-1 basic domain/leucine zipper (HBZ) protein could also contribute to retroviral carcinogenesis (Ma et al., 2013; Arnold et al., 2006 Arnold et al., , 2008 Zhi et al., 2011; Zhao et al., 2011 Zhao et al., , 2013 Kuhlmann et al., 2007; Matsuoka and Jeang, 2007; Satou et al., 2006) . The HBZ product is translated from an antisense pX transcript made from the 3 0 long-terminal repeat (LTR; Matsuoka and Jeang, 2007; Satou et al., 2006) , and has been shown to induce expression of the human telomerase reverse transcriptase (hTERT) gene through the activation of JunD, associated with aberrant T-cell lymphoproliferation and immortalization (Kuhlmann et al., 2007; Matsuoka and Jeang, 2007; Satou et al., 2006) . Zhi et al. (2011) have demonstrated that HBZ counters Tax-induced cellular senescence by inhibiting NF-kappaB activation. Moreover, HBZexpressing transgenic mice exhibit systemic inflammation, particularly, of the skin and lungs, and develop T-cell lymphomas . In addition to these findings, we have previously demonstrated that the p30 II accessory protein cooperates with the c-MYC oncoprotein and activates c-MYC dependent transcription -associated with increased S-phase cell-cycle entry, multinucleation, and oncogenic transformation/foci-formation by p30 II /c-MYC (Awasthi et al., 2005) .
The HTLV-1 encodes three latency-maintenance factors: p30 II , HBZ, and p13
II (Johnson et al., 2001; Kannian and Green, 2010; Lairmore et al., 2012; Nicot et al., 2005; Edwards et al., 2011; Silic-Benussi et al., 2010; Bai and Nicot, 2012; Arnold et al., 2006; Awasthi et al., 2005; Li et al., 2009; Bai et al., 2010; Anupam et al., 2013; Michael et al., 2006; Zhang et al., 2000 Zhang et al., , 2001 Nicot et al., 2004; Younis et al., 2004 Younis et al., , 2006 Bartoe et al., 2000; Silverman et al., 2004; Clerc et al., 2008; Lemasson et al., 2007; Andresen et al., 2011) , which negatively regulate viral gene expression and may help HTLV-1-infected cells evade host immune-surveillance pathways as a prerequisite for viral persistence and the development of malignant disease after many years Silverman et al., 2004) . The antisense protein, HBZ, interacts with the kinase-inducible exchange (KIX) and histone acetyltransferase (HAT) domains of the transcriptional coactivators, p300/CBP, and inhibits Tax-dependent transactivation from the HTLV-1 promoter by interfering with Tax-p300/CBP binding (Wurm et al., 2012; Clerc et al., 2008) . Lemasson et al. (2007) have also shown that HBZ directly interacts with CREB/ATF-1 transcription factors and prevents their recruitment into Tax-CREB nucleoprotein complexes on the viral promoter. The p30 II protein (also known as Tax-Open Reading Frame II, or Tof-II) is comprised of 241 amino acid residues and contains arginine-and serine/threonine-rich regions which share sequence similarities with POU-family homeodomain transcription factors, Oct-1/2 and Pit-1, and is translated from an alternative doubly-spliced pX mRNA (Johnson et al., 2001; Koralnik et al., 1993; Nicot et al., 2005; Bai and Nicot, 2012; Bai et al., 2010; Anupam et al., 2013) . p30 II contains three nuclear localization signals: NLS1 (residues 66-73), NLS2 (residues 91-98), and NLS3 (residues 200-220) and two putative nucleolar localization/retention signals: NoLS1 (residues 73-78) and NoLS2 (residues 91-98) (Koralnik et al., 1993; Nicot et al., 2005; Bai et al., 2010; Anupam et al., 2013; Ghorbel et al., 2006) , as well as a functional transcriptional activation domain, spanning amino acid residues 62-220 which was characterized using Gal4 (DBD)-p30 II fusion/UAS transactivation experiments (Zhang et al., 2000 (Zhang et al., , 2001 . The p30 II protein suppresses the expression of HTLV-1 antigens through distinct transcriptional and posttranscriptional mechanisms. Zhang et al. (2001) have demonstrated p30 II binds to the KIX domain of p300/ CBP and inhibits Tax-dependent transactivation from the viral promoter through competitive interactions with p300/CBP. The ability of p30 II to interfere with Tax-dependent transactivation was dependent upon a single lysine residue at position 106 (K106) within the p30 II protein and also required p300 HAT activity (Michael et al., 2006) . By contrast, Nicot et al. (2004) and Younis et al. (2004) have shown that p30 II inhibits HTLV-1 gene expression by sequestering tax/rex mRNAs within nucleoli, thereby preventing their nuclear export. The related p28 II protein of HTLV-2 similarly inhibits the nuclear export of tax/rex transcripts (Younis et al., 2004 . Although the mechanism(s) by which p30 II posttranscriptionally regulates viral and cellular gene expression remains to be fully elucidated (Nicot et al., 2004; Younis et al., 2004 Younis et al., , 2006 Taylor et al., 2009 ), Younis et al. (2006) have demonstrated that p30 II is recruited to Tax-containing transcription complexes on the HTLV-1 promoter and travels together with the RNA Pol II elongation complex until it reaches a downstream target mRNA structural element. The p13 II protein, which corresponds to amino acids 155-241 of the carboxyl-terminus of p30 II , in its ubiquitinated form, has also been shown to negatively regulate HTLV-1 gene expression by inhibiting the ability of Tax to bind to the transcriptional coactivators p300/CBP (Andresen et al., 2011) .
In addition to its role in maintaining viral latency, we have demonstrated that p30 II cooperates with c-MYC and augments c-MYC-dependent transcriptional and oncogenic functions through interactions with the MYST-family acetyltransferase, TIP60, on c-MYC-responsive gene promoters (Awasthi et al., 2005) . Acute and lymphoma-stage ATLL patient isolates frequently over-express c-MYC, fluorescence-microscopy (top panels) and immunoblotting. The subcellular distributions of HTLV-1 p30 II -GFP and GFP were determined by direct fluorescence-microscopy.
Scale bars in the micrographs represent 100 μm. (B) Cells were co-transfected with a human cyclin D2 promoter-luciferase reporter plasmid (0.5 μg) and increasing amounts (1.0, 2.0 μg) of CMV-HTLV-1 p30 II -GFP or pcDNA3.1-GFP. (C) The cells were co-transfected as in B with a mutant cyclin D2 MUT promoter-luciferase construct which lacks conserved E-box elements in the presence of increasing CMV-HTLV-1 p30 II -GFP or pcDNA3.1-GFP. (D) Cells were co-transfected with a human cyclin D2 promoter-luciferase reporter plasmid and CMV-HTLV-1 p30 II -GFP in the presence of increasing amounts of CMV-wildtype TIP60 or CMV-TIP60 Q377E/G380E (1.0, 3.0 μg) (Ikura et al., 2000) . (E) 293A
HEK cells were co-transfected with a cyclin D2 promoter-luciferase reporter plasmid and CMV-HTLV-1 p30 II -GFP. The cells were also repeatedly transfected with an siRNA targeted against tip60 (siRNA-tip60) or a non-specific RNA (nsRNA) control. The HTLV-1 p30 II -GFP and GFP proteins were visualized by direct-fluorescence microscopy (upper right panels). The inhibition of endogenous TIP60 protein expression by the transfected siRNA-tip60 was demonstrated by immunoblotting (lower panels). Actin is shown as a control for equivalent protein loading. A tk-renilla luciferase construct was co-transfected as a control for transfection efficiencies (not shown) and dual-luciferase measurements were performed. The reported activities were normalized for equivalent renilla-luciferase activities. Koralnik et al., 1993) , p300, c-MYC, and TIP60 as in Awasthi et al. (2005) . Non-specific rabbit IgG was included as a control.
The precipitated oligonucleosomal DNA fragments were detected by PCR amplification using the prm primer pair; the utr primers were used as a negative control (top panels). Dual-ChIPs (lower panels) were performed by re-immunoprecipitating nucleoprotein complexes using individual antibodies against HTLV-1 p30 II , p300, c-MYC, TIP60, or non-specific IgG as described in Vakoc et al. (2005) . The re-precipitated DNA fragments were detected by PCR using the prm primers.
as a result of 8q24 chromosomal translocations and/or c-myc locus gene amplification, associated with an aggressive disease phenotype and poor clinical outcomes (Awasthi et al., 2005; Mengle-Gaw and Rabbitts, 1987; Okumura et al., 2012; Koizumi et al., 1989; Saggioro et al., 1999; Hall et al., 1998; Miyazaki et al., 1996; Duyao et al., 1992) . The viral Tax protein transactivates NF-kappaB elements within the c-myc promoter (Duyao et al., 1992) . However, Gabet et al. (2003) have shown that Tax represses c-MYC-dependent transactivation from the hTERT gene promoter, and Semmes et al. (1996) have also demonstrated Tax inhibits c-MYC-dependent transcription and anchorageindependent cell growth. Interestingly, tumors in tax transgenic mice exhibit high levels of apoptosis associated with increased oncogene expression, including c-MYC (Saggioro et al., 1999; Hall et al., 1998) . Thus, the cooperation between p30 II and c-MYC may provide a mechanism whereby the viral pX proteins (p30 II , Tax, and/or HBZ) coordinately regulate oncogene-activation, while inhibiting c-MYCinduced apoptosis, to promote proviral replication and the proliferation of HTLV-1-infected T-cells.
The c-MYC oncoprotein is acetylated on multiple lysine residues by the transcriptional cofactors/acetyltransferases, p300/CBP, PCAF/GCN5, and TIP60 Zhang et al., 2005; Vervoorts et al., 2003; Patel et al., 2004; Vervoorts et al., 2006; Mao et al., 2011) . Faiola et al. (2005) have demonstrated that p300-mediated lysine-acetylation of c-MYC is associated with increased turnover and degradation of the c-MYC protein. This is in contrast to the role of acetylation by PCAF/GCN5 and TIP60, which has been shown to stabilize and significantly increase the half-life of c-MYC (Patel et al., 2004) . Conversely, the Max protein, another basic domain/helix-loop-helix/leucine zipper (bHLHZip)-family transcription factor that regulates c-MYC functions, is acetylated on lysine residues K57, K144, and K145 which is important for its nuclear localization in mammalian cells (Faiola et al., 2007) . It is important to note that, as many of the acetylation sites within c-MYC have been identified through in vitro biochemical studies, the role of site-specific acetylation in c-MYC biological functions remains to be fully determined.
The present study provides new insight into the mechanism(s) of cooperation between p30 II and c-MYC, and demonstrates that p30 II induces acetylation of the c-MYC oncoprotein which is required for oncogenic foci-formation by p30 II /c-MYC (Awasthi et al., 2005) . These findings allude to a possible role for c-myc oncogene-activation and its cooperation with retroviral accessory proteins during proviral replication and HTLV-1-associated T-cell leukemogenesis. The relative expression of p30 II -GFP and GFP was determined by immunoblotting (Fig. 1A) . As shown in Fig. 1A , higher levels of cyclin D2 were observed to coincide with increasing amounts of HTLV-1 p30 II -GFP, relative to the GFP control. The subcellular distribution of p30 II -GFP was predominantly nuclear/nucleoplasmic, whereas GFP exhibited a whole-cell fluorescence pattern (Fig. 1A, right panels) . We have previously demonstrated that the HTLV-1 p30 II (HA-tagged) protein interacts with the c-MYC oncoprotein and transactivates c-MYC-responsive E-box enhancer elements within the human cyclin D2 promoter, dependent upon recruitment of the MYST-family acetyltransferase TIP60 (Awasthi et al., 2005) . Therefore, we next tested whether the p30 II -GFP fusion similarly modulates c-MYC-dependent transactivation. Results in Fig. 1B demonstrate that increasing amounts of the CMV-HTLV-1 p30 II -GFP expression construct transcriptionally activate a human cyclin D2 promoter-luciferase reporter gene, as compared to the pcDNA3.1-GFP control. The ability of p30 II -GFP to transactivate the cyclin D2 promoter was dependent upon the conserved c-MYC-responsive E-box enhancer elements, as a mutant cyclin D2 MUT promoter-luciferase reporter lacking the E-boxes (Vervoorts et al., 2003) was not transactivated by increasing p30 II -GFP (Fig. 1C) . Consistent with our earlier findings that p30
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II stabilizes the recruitment of the transcriptional cofactor/acetyltransferase TIP60 to p30 II /c-MYC nuclear complexes (Awasthi et al., 2005) , over-expression of wildtype TIP60 resulted in significantly higher transactivation of the cyclin D2 promoter by p30 II -GFP (Fig. 1D) . A dominant-negative TIP60 Q377E/G380E mutant, defective for acetyltransferase activity (Ikura et al., 2000) , inhibited p30 II -GFP-mediated transactivation (Fig. 1D ). We next tested the effects of inhibiting TIP60 expression using a small-interfering RNA targeted against tip60 transcripts (siRNA-tip60) upon p30 II -GFP-dependent transactivation from the cyclin D2 promoter. A non-specific RNA (nsRNA) was included as a negative control. Results in Fig. 1E demonstrate that increasing amounts of transfected siRNA-tip60 inhibited p30 II -GFPdependent transcriptional activation, compared to the nsRNA. The inhibition of endogenous TIP60 protein expression by siRNA-tip60 was verified by immunoblotting ( Fig. 1E , bottom right). The p30 II -GFP and GFP proteins were visualized by direct-fluorescence microscopy ( Fig. 1E , upper right panels). These results collectively agree with our previous observations in Awasthi et al. (2005) cells, we performed immunofluorescence-microscopy using an anti-FLAG antibody, and then quantified the relative fluorescence intensities of the TIP60-FLAG proteins within individual cells with Zeiss Axiovision 4.8 software. As shown in Fig. 1F and G, the TIP60-FLAG proteins were comparably expressed in co-transfected 293A cells containing either CMV-HTLV-1 p30 II -GFP or the CβS empty vector.
Recruitment of the acetyltransferases TIP60 and p300 to p30 II /c-MYC transcription complexes in HTLV-1-transformed T-cells
Using chromatin-immunoprecipitations (ChIPs), we have shown that the retroviral p30 II accessory protein is recruited, together with c-MYC and its associated transcriptional cofactors TIP60, p300, and TRRAP/p434, to E-box enhancer elements within the cyclin D2 fibroblasts by immunofluorescence-microscopy. A pcDNA3.1-GFP expression construct was included as a negative control. The graphs at right were generated using Zeiss AxioVision 4.8 software and represent a heat-map of colocalization for the indicated areas (dotted lines). DIC phase-contrast images with DAPI nuclear-staining are shown for reference. The scale bars represent 10 μM. UT, untransfected cells.
promoter in HTLV-1-transformed T-lymphocytes (Awasthi et al., 2005) . Now, extending these findings, we have used dual-ChIPs (Vakoc et al., 2005) to determine if p30 II , c-MYC, TIP60, and p300 are present within the same nucleoprotein complex assembled on E-box elements in the cyclin D2 promoter in HTLV-1-transformed HuT-102 T-cells. In the dual-ChIP assay, cross-linked bound oligonucleosomal protein complexes are initially immunoprecipitated using individual antibodies and Protein A-agarose in a standard ChIP. However, the ChIP-ed complexes are then re-immunoprecipitated from each sample using a second series of antibodies to detect factors that are present together in a single nucleoprotein complex (Vakoc et al., 2005) . As shown in Fig. 1H , we now provide the first evidence that p30 II (immunoprecipitated using the rabbit polyclonal anti-HTLV-1 p30 II , Peptide B, antibody -kindly provided by Dr. G. Franchini, NCI/ NIH; Koralnik et al., 1993 ) is recruited with c-MYC, TIP60, and p300 to E-boxes in the cyclin D2 promoter in HTLV-1-transformed T-lymphocytes. Non-specific rabbit IgG was included as a negative ChIP control (Fig. 1H) . Intriguingly, in complementary dual-ChIPs, TIP60 and p300 seemed to only weakly associate, which suggests these individual factors may be separated in the p30 II /c-MYC complex (Fig. 1H) .
Acetylation-defective Lys-Arg c-MYC substitution mutants are impaired for oncogenic cellular transformation by p30 II /c-MYC
To determine if lysine-acetylation of the c-MYC oncoprotein is required for its cooperation with p30 II (Awasthi et al., 2005) , we performed in vitro cell transformation/foci-formation assays using c-myc À /À HO15.19 rodent fibroblasts which are knocked out for the c-myc gene (Albihn et al., 2006; Mateyak et al., 1997) . The cultures were cotransfected with CMV-HTLV-1 p30 II -GFP or a pcDNA3.1-GFP control, and either CβF-wildtype c-MYC or expression constructs for the acetylation-impaired Lys-Arg mutants, c-MYC K323R/K417R (Patel et al., 2004) or c-MYC R5 . Colony formation -indicative of a loss of cellular contact-inhibition associated with oncogenic transformation (Awasthi et al., 2005) , was observed following 2 weeks and the transformed foci were stained with methylene blue for enhanced visualization ( Fig. 2A and B) . The c-myc À / À HO15.19 fibroblasts grow as a monolayer and typically exhibit a senescence-like cellular morphology and reduced proliferative rate, as compared to the parental TGR-1 rat fibroblasts which are more spindle-shaped (Fig. 2B, right panels) . The coexpression of wildtype c-MYC together with the GFP control did not result in significant foci-formation (approximately 6 colonies for c-MYC/GFP, versus 7 colonies for untransfected cells; Fig. 2A and C) .
In agreement with our previous data in Awasthi et al. (2005) , the xc-MYC oncoprotein cooperated with HTLV-1 p30 II to induce oncogenic cellular transformation and resulted in approximately 42 colonies ( Fig. 2A-C) . The expression of p30 II -GFP within transformed colonies was visualized by direct fluorescence-microscopy ( Fig. 2B) . Importantly, the acetylation-impaired Lys-Arg c-MYC mutants, K323/K417R and R5, were defective for oncogenic transformation and cooperation with p30 II (Fig. 2C) , suggesting that acetylation of the c-MYC oncoprotein might be required for its molecular interactions with p30 II (Awasthi et al., 2005; Faiola et al., 2005; Vervoorts et al., 2003; Patel et al., 2004) . Consistent with these findings, the co-expression of increasing amounts of various dominant-negative acetyltransferase mutants: TIP60 Q377E/G380E , PCAF ΔHAT , and p300 ΔE1A (Moser et al., 2000; Ikura et al., 2000; Chakravarti et al., 1999; Yang et al., 1996) , inhibited HTLV-1 p30 II /c-MYC-induced oncogenic cellular transformation in vitro in the wrn À / À WS AG11395 fibroblast cell-line, which was the line used to originally demonstrate the oncogenic cooperation between p30 II and c-MYC ( Fig. 2D ; Awasthi et al., 2005) . We recognize, however, that these dominant-negative coactivator mutants are likely to have a pleiotropic negative impact upon cellular transcription as well as cell proliferation in general. Fig. 3A and B) . The expression of HTLV-1 p30 II -GFP, GFP, and c-MYC proteins was detected by immunofluorescencemicroscopy. Untransfected c-myc À /À HO15.19 or HeLa cells (UT) and pcDNA3.1-GFP were included as negative controls ( Fig. 3A and B) . The p30 II -GFP fusion localized to the nucleus/nucleolus with a subfraction distributed throughout the cytoplasm, whereas GFP exhibited a whole-cell fluorescence pattern (Fig. 3A and B) . Further, we demonstrated that the p30 II -GFP co-immunoprecipitates with FLAG epitopetagged wildtype c-MYC, as well as the acetylation-defective Lys-Arg c-MYC mutants, K323R/K417R and R5, in whole-cell extracts prepared from cotransfected 293T HEK cells (Fig. 4A) . These results suggest the impairment in the cooperation between HTLV-1 p30 II and the LysArg c-MYC mutants (Fig. 2C) is not derived from impaired molecular interactions with p30 II , but, rather, could reflect the defective acetylation status of the c-MYC mutant proteins Patel et al., 2004) .
A diagram of the c-MYC oncoprotein depicting its acetylation sites is shown in Fig. 4B epitope-tagged c-MYC in cotransfected 293 HEK cells, as compared to an empty vector control (Fig. 4C) . The acetylated c-MYC protein was immunoprecipitated using an anti-Acetyl-Lysine antibody (Millipore) and detected by immunoblotting as described in Patel et al. (2004) ; Fig. 4C . We also observed that c-MYC is acetylated in HTLV-1-transformed T-cell-lines, HuT-102 and MJG11 (Fig. 4D) . Uninfected Jurkat lymphoblastic leukemia cells were included for comparison (Fig. 4D) . The endogenous p30 II protein was detected in HTLV-1-infected cells using the rabbit polyclonal Peptide B antibody (Koralnik et al., 1993) . The acetylated c-MYC oncoprotein was immunoprecipitated using an anti-Acetyl-Lysine antibody as described; and an anti-GFP antibody was included as a control for IP specificity (Fig. 4D , lower panel). These findings together suggest that acetylation of the c-MYC protein is required for its oncogenic cooperation with p30 control. Cells were also treated with the sphingolipid C2-ceramide as a positive control for apoptosis. Programmed cell death was detected and quantified by staining the cotransfected cultures with Annexin-V-FITC and propidium iodide (BD-Pharmingen) and subsequent analysis by flow cytometry. We did not observe significant differences in cellular apoptosis for the wildtype c-MYC or acetylation-defective mutant proteins, relative to the control, when expressed alone in the c-myc À /À HO15.19 background (Fig. 5A ).
Apoptosis was also visualized by Annexin-V-FITC-staining and immunofluorescence microscopy in cotransfected c-myc
HO15.19 cells as well as transformed foci expressing p30 II (HA)/c-MYC (Fig. 5B) . Surprisingly, with prolonged 12-h labeling of the cotransfected cells with bromodeoxyuridine (BrdU) for flow cytometric cell-cycle analyses, we found that c-MYC-expressing cells exhibited significantly more apoptosis than p30 II /c-MYC-expressing cells, which also contained polyploidy as noted in Awasthi et al. (2005;  Fig. 5C ). We therefore cotransfected HO15.19 fibroblasts to express various combinations of wildtype c-MYC or the Lys-Arg acetylation-defective mutants, K323R/K417R and R5, together with HTLV-1 p30 II (HA) or empty vector control, and subsequently treated the cultures for 12-hr with BrdU. Then the cells were stained with Annexin-V-FITC and apoptosis was measured by visually counting, in triplicate, the numbers of Annexin-V-FITC-positive cells per field (Fig. 5D) . Results shown in Fig. 5D and graphed in Fig. 5E demonstrate that the c-MYC/empty CβS vector combination induced high levels of apoptosis, as compared to cells expressing p30 II (HA)/c-MYC ( Fig. 5D and E) . The K323R/K417R and R5 acetylation-defective mutants did not induce significant apoptosis in the presence of prolonged BrdU treatment ( Fig. 5E ; data not shown), which may reflect a general functional impairment of these mutants in their ability to promote cellular proliferation. A representative experiment is shown in Fig. 5F against Camptothecin-induced apoptosis, compared to cells containing the ACH.30.1 mutant defective for p30 II production. Similar to Camptothecin, genomic BrdU-incorporation produces DNAdamage (single strand breaks) and genotoxic stress and cytotoxicity (Ackland et al., 1988) Fig. 6A and B). Consistent with our previous observations (Awasthi et al., 2005) , p30 II -GFP expression resulted in significantly more multinucleation in the presence of etoposide (4 6%, Fig. 6A and B), which could possibly be attributed to the induction of c-MYC and aberrant DNA-endoreduplication following p53-dependent G2/M-arrest (Awasthi et al., 2005; Datta et al., 2007) . We and others have shown that p30 II induces the accumulation of cells in the G2-phase of the cell cycle (Awasthi et al., 2005; Datta et al., 2007) . As p53 regulates the G2/M checkpoint through the induction of regulatory factors, including 14-3-3σ and p21 Waf/Cip1 (Chan et al., 2000) , we therefore examined p53 expression in p30 II -GFP-expressing cells in the presence or absence of etoposide. These studies revealed that p53 protein levels were increased in both p30 II -GFP-expressing and etoposide-treated HFL1 fibroblasts (Fig. 6B) . To determine whether p30 II might promote c-MYC-dependent DNA endoreduplication in etoposide-treated cells, we next transduced HFL1 fibroblasts with a lentiviral vector expressing HTLV-1 p30 II (HA-tagged), or an empty lentiviral vector, and then treated the cultures with etoposide as described. The cells were subsequently labeled with BrdU for 6 h and stained with an antiBrdU-FITC antibody (BD Pharmingen) to identify cells in the S-phase of the cell cycle. The HTLV-1 p30 II (HA) protein was detected by immunofluorescence-microscopy ( Fig. 6C, lower panels) . These results demonstrate that p30 II -expressing cells incorporated the BrdU deoxynucleotide analog into their genome under conditions of etoposide-treatment (Fig. 6C) . We were not able to detect c-MYCacetylation in the etoposide-treated cells, which express low levels of full-length c-MYC (data not shown). Conacci-Sorrell et al. (2014) recently reported the majority of c-MYC is cleaved by the Calpain protease into a truncated form (designated 'MYC-nick'), containing amino acid residues 1-298, in the presence of etoposide. This proteolytic processing would remove lysine residues K323 and K417 which were identified as putative targets for acetylation by TIP60 (Patel et al., 2004) . Therefore, the levels of acetylated fulllength c-MYC may be too low to detect using our current IP methods in etoposide-treated cells.
Our results allude to a mechanistic model whereby p30 II induces acetylation of the c-MYC oncoprotein to augment its transcriptional activity, and inhibits c-MYC-dependent cellular apoptosis in the presence of genotoxic stress -which could lead to the increased accumulation of somatic mutations and genomic instability associated with oncogenic transformation and viral carcinogenesis ( Fig. 7 ; Awasthi et al., 2005) . As DNA-damageinducing agents, such as etoposide, hydroxydaunorubicin, and cyclophosphamide are used in the CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin, prednisolone) anticancer chemotherapy regimen for the clinical management of ATLL, our present findings suggest that retroviral proteins, such as p30 II , may interfere with the cytopathic killing effects of these drugs and could promote the accumulation of somatic mutations which could contribute to disease progression.
Discussion
We are studying how the persistently expressed latencymaintenance factors (i.e., p30 II , HBZ, p13 II ) of HTLV-1 influence host cellular pathways to promote proviral replication and contribute to disease progression during viral carcinogenesis (Nicot et al., 2005; Bai and Nicot, 2012; Arnold et al., 2006; Awasthi et al., 2005; Li et al., 2009; Bai et al., 2010; Anupam et al., 2013; Michael et al., 2006; Zhang et al., 2001; Nicot et al., 2004; Younis et al., 2004 Younis et al., , 2006 Bartoe et al., 2000; Silverman et al., 2004; Clerc et al., 2008; Lemasson et al., 2007; Andresen et al., 2011) . Whereas the transactivator protein, Tax, is recognized to play a pivotal role during the earliest stages of T-cell immortalization and oncogenesis (Johnson et al., 2001; Kannian and Green, 2010; Currer et al., 2012; Hasegawa et al., 2006; Swaims et al., 2010; Rauch et al., 2009; Mitra-Kaushik et al., 2004; Grossman and Ratner, 1997) , other viral pX factors (p30 II , p13 II , and HBZ) have been shown to negatively regulate proviral gene expression and inhibit Tax-dependent transactivation of the HTLV-1 5 0 LTR (Nicot et al.,2004 (Nicot et al., , 2005 Bai and Nicot, 2012; Arnold et al., 2006; Bai et al., 2010; Anupam et al., 2013; Michael et al., 2006; Zhang et al., 2001; Younis et al., 2004 Younis et al., , 2006 Silverman et al., 2004; Clerc et al., 2008; Lemasson et al., 2007; Andresen et al., 2011) . These proteins help to maintain latency by suppressing the expression of viral antigens which is required for HTLV-1-infected T-lymphocytes to evade host immunesurveillance pathways and establish long-term proviral persistence (Johnson et al., 2001; Nicot et al., 2005; Edwards et al., 2011; Bai and Nicot, 2012; Arnold et al., 2006; Li et al., 2009; Bai et al., 2010; Anupam et al., 2013; Bartoe et al., 2000; Silverman et al., 2004) . The p30 II accessory protein contains a transcriptional activation domain between amino acid residues 62-220 and interacts with the transcriptional cofactors, p300/CBP and TIP60 (Awasthi et al., 2005; Michael et al., 2006; Zhang et al., 2000 Zhang et al., , 2001 . We and others have published microarray gene expression analyses of cellular target genes whose expression is activated or repressed by p30 II (Awasthi et al., 2005; Taylor et al., 2009; Michael et al., 2004) . In the Awasthi et al. (2005) study, by including a dominant-negative TIP60 Q377E/G380E HAT mutant (Ikura et al., 2000) , we identified several downstream target genes transcriptionally activated by p30 II whose expression is dependent upon the TIP60 acetyltransferase. p30 II differentially regulates CREBdependent transcription, and inhibits Tax-quaternary complex formation with CREB and p300 on 21-bp-repeat Tax-responsive elements (TREs) through binding to the KIX domain of p300 (Michael et al., 2006; Zhang et al., 2000 Zhang et al., , 2001 . Datta et al. (2006) have also shown that p30 II inhibits DNA-binding by PU.1 and represses (Toll-like receptor-4) TLR4 inflammatory signaling in macrophages. These studies were recently extended by Fenizia et al. (2014) , who demonstrated that p30 II inhibits the expression of interferon-responsive genes following lipopolysaccharide-stimulation of TLR3 and TLR4 in monocytes and dendritic cells, which may contribute to a permissive cellular phenotype during early-stage infection as well as throughout the course of persistent disease. We have previously demonstrated that p30 II interacts with TIP60 and enhances c-MYC-dependent transcriptional activation and oncogenic potential (Awasthi et al., 2005) . However, the molecular mechanism(s) by which p30 II cooperates with c-MYC remains to be fully elucidated. Herein, we have shown that p30 is recruited to c-MYC/TIP60/p300 transcriptional complexes on E-box enhancer elements within the endogenous cyclin D2 promoter in HTLV-1-transformed HuT-102 T-lymphocytes using dual-ChIPs (Fig. 1H) . p30 II induces acetylation of the c-MYC oncoprotein in transfected 293 cells (Fig. 4C) ; and c-MYC is also strongly acetylated in the HTLV-1-infected T-cell-lines HuT-102 and MJG11 (Fig. 4D ). In the Awasthi et al. (2005) study, we demonstrated that amino acid residues 99-154 of p30 II interact with the TIP60 acetyltransferase, which functions as a transcriptional cofactor and has been shown to acetylate the c-MYC protein (Patel et al., 2004; Frank et al., 2003) . The specific sites of TIP60-mediated acetylation within c-MYC are yet to be identified (Patel et al., 2004) . Furthermore, we found that the acetylation-defective Lys-Arg substitution mutants of c-MYC (R5 and K323R/K417R) are impaired for oncogenic cellular transformation/foci formation with p30 II in cotransfected c-myc À /À HO15.19
fibroblasts (Fig. 2AÀ C) . We did not observe discernable differences in cellular apoptosis induced by wildtype c-MYC or the acetylation-defective c-MYC mutants K323/R/K417R or R5 in the presence of p30 II in cotransfected c-myc À / À HO15.19 fibroblasts (Fig. 5A and B) . As Datta et al. (2007) have reported that p30 II expression inhibits apoptosis induced by genotoxic stress in Camptothecin-treated primary T-lymphocytes transduced with an HTLV-1 ACH proviral clone, we next tested whether c-MYC-acetylation plays a role in the ability of p30 II to protect against cell-death induced by DNA-damage-inducing agents. Interestingly, p30 II significantly inhibited c-MYC-dependent apoptosis caused by prolonged exposure to BrdU, which induces single-strand DNA breaks ( Fig. 5C-F ; Ackland et al., 1988) . Neither of the acetylation-defective c-MYC mutants resulted in increased apoptosis in BrdU-treated cells (Fig. 5C-F ). This could be attributed to an inability of these mutants to restore normal cell-cycle functions and genomic replication in transfected c-myc À /À HO15.19 fibroblasts, as compared to wildtype c-MYC. We also observed that p30 II results in an increased number of multinucleate cells in the presence of the genotoxic chemical, etoposide (Fig. 6A and B) . These findings collectively agree with our previous results (Awasthi et al., 2005) and those in Datta et al. (2007) , as well as the report by Baydoun et al. (2011) that p30 II promotes error-prone nonhomologous-end-joining DNArepair. Doueiri et al. (2012) have reported a list of proteins detected in the interactomes of S-tagged HTLV-1 p30 II and related HTLV-2 p28 II proteins, based upon S-tag affinity purification and mass spectrometric/proteomic analyses. Noticeably, however, these studies failed to detect interactions between p30 II and TIP60, c-MYC, or other known p30 II -binding partners including p300/CBP, CREB, PU.1, and large ribosomal subunit protein L18a (Awasthi et al., 2005; Michael et al., 2006; Zhang et al., 2000 Zhang et al., , 2001 Ghorbel et al., 2006; Datta et al., 2006; Doueiri et al., 2012) . Using the I-TASSER computational protein-folding and structure prediction algorithm (University of Michigan, 〈http:// zhanglab.ccmb.med.umich.edu/I-TASSER/〉), we determined that the TIP60-binding domain (aa residues 99-154; Awasthi et al., 2005) of the S-tagged p30 II protein is predicted to be misfolded and likely inaccessible, compared to the wildtype p30 II protein structure ( Supplementary Fig. S1 ). Thus, albeit intriguing, the significance of the interacting factors identified through this proteomic screen remains to be determined until the biological functionality (e.g., inhibition of Tax-dependent transactivation, cooperation with oncoproteins, or nuclear sequestration of tax/rex mRNA) of the S-tagged p30 II protein has been demonstrated (Doueiri et al., 2012) .
The c-MYC oncoprotein is frequently overexpressed in acute and lymphoma-stage ATLL clinical isolates, as a result of 8q24 chromosomal translocations and/or c-myc locus gene amplification (Awasthi et al., 2005; Mengle-Gaw and Rabbitts, 1987; Okumura et al., 2012; Koizumi et al., 1989; Saggioro et al., 1999; Hall et al., 1998; Miyazaki et al., 1996; Duyao et al., 1992) . c-MYC regulates cellular proliferation and differentiation (Link et al., 2012; Takahashi et al., 2007; Soufi et al., 2012) , and has been shown to function as a non-linear amplifier of transcriptionally active genes in lymphocytes and embryonic stem cells (Nie et al., 2012) . While it is assumed the primary purpose of p30 II 's cooperation with c-MYC is to promote proviral replication in HTLV-1-infected cells (Awasthi et al., 2005) , these molecular interactions could contribute to disease progression associated with c-MYC deregulation in acute T-cell leukemia or lymphoma-stage ATLL (Mengle-Gaw and Rabbitts, 1987; Okumura et al., 2012; Koizumi et al., 1989; Saggioro et al., 1999; Hall et al., 1998; Miyazaki et al., 1996; Duyao et al., 1992) . Our findings further suggest that p30 II (and other HTLV-1 proteins) may interfere with the cytopathic effects of CHOP-regimen DNA-damage-inducing chemotherapy drugs, such as etoposide, hydroxydaunorubicin, or cyclophosphamide, used in the clinical management of ATLL and could promote the accumulation of somatic mutations which may lead to the development of advanced acute-or lymphoma-stage disease. Therefore, it is intriguing to speculate that it may become possible to sensitize ATLL tumor lymphocytes to oncogene-induced apoptosis in the presence of DNA-damage-inducing chemotherapy drugs by targeting the latency-maintenance factor p30 II and/or its interactions with host cellular components.
Materials and methods
Cell culture and transfections
293 HEK cells (ATCC, CRL-1573), 293A (Quantum Biotechnology) and 293T/17 (ATCC, CRL-11268) cells were seeded at 2 Â 10 5 cells/ well in six-well plates or 60 mm 2 tissue-culture dishes (Nalge) and cultured in ATCC 46-X medium or Eagle's minimum essential medium (EMEM; ATCC) supplemented with sodium bicarbonate (Invitrogen), 10% fetal bovine serum (FBS; Atlanta Biologicals, Biowest), 100 U/ml penicillin, and 100 μg/ml streptomycin sulfate (Invitrogen) at 37 1C under 5% CO 2 . For certain experiments, 293A HEK cells were cultured in the presence of 2% FBS. Immortalized human wrn À / À WS fibroblasts (AG11395) (Moser et al., 2000) , parental TGR1 and c-myc À / À HO15.19 rat fibroblasts (Albihn et al., 2006; Mateyak et al., 1997) , and HeLa cells (ATCC, CCL-2) were grown in Dulbecco's modified Eagle's medium (DMEM; ATCC) supplemented as described. The HFL1 human fetal lung fibroblast cell-line (ATCC, CCL-153) was cultured in F-12K medium. HTLV-1-transformed T-cell lines, HuT-102 (ATCC, TIB-162) and MJG11 (ATCC, CRL-8294), and Jurkat E6.1 T-lymphocytes (ATCC, TIB-152) were cultured in RPMI 1640 medium (ATCC) supplemented with 20% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin sulfate (Invitrogen), and 20 μg/ml gentamicin sulfate (SIGMA-Aldrich).
The N3-CMV-HTLV-1 p30 II -GFP and pMH-CMV-HTLV-1 p30 II (HA-tagged) expression constructs (Nicot et al., 2004) , human cyclin D2 promoter-luciferase and cyclin D2 MUT -luciferase reporter plasmids (Vervoorts et al., 2003; Bouchard et al., 2001 ), pOZ-CMV-TIP60 and pOZ-CMV-TIP60 Q377E/G380E (Ikura et al., 2000) , pSI-CMVp300 ΔE1A and pCX-CMV-PCAF ΔHAT (Chakravarti et al., 1999; Yang et al., 1996) , CβF-CMV-wildtype c-MYC (FLAG-tagged) and CβF-CMV-Lys-Arg c-MYC mutants: K323R/K417R and R5 Patel et al., 2004; McMahon et al., 1998) have been previously described. The c-MYC R5 combinatorial mutant contains the following Lys-Arg substitution mutations: K144R/K149R/K158R/K317R/ K323R . All transfections were carried out using SuperFect (Qiagen) or Lipofectamine-Plus (Invitrogen) reagents as recommended in the manufacturers' protocols. Luciferase assays were performed using the Dual-Glo Luciferase Assay System (Promega, Inc.).
To inhibit endogenous TIP60 protein expression using small interfering-RNAs (siRNAs), 293A HEK cells were repeatedly transfected with increasing amounts (0.25 and 0.5 μg) of a bridged nucleic acid (BNA) RNA oligonucleotide targeted against tip60 transcripts (siRNA-tip60): 5'-AACCCCUCCACCUUCCG þT-phosphorothioate-3 0 , or a non-specific RNA (nsRNA) BNA oligonucleotide:
0 (Biosynthesis, Inc.) as a negative control. All RNA transfections were performed using the HiPerfect transfection reagent (Qiagen, Inc.) as recommended in the manufacturer's protocol.
Chromatin-immunoprecipitations and dual-ChIPs
Chromatin-immunoprecipitations were performed by crosslinking c-MYC-containing nucleoprotein complexes in vivo by treating cultures with 270 μl of 37% formaldehyde for 10 min at 37 1C under 5% CO 2 . The cells were pelleted by centrifugation and resuspended in 200 μl SDS-Lysis Buffer (Upstate Biotechnology). Chromatin DNA was fragmented by sonication, and oligonucleosomal/nucleoprotein complexes were precipitated using primary antibodies and 60 μl salmon sperm DNA/Protein A-agarose (Upstate Biotechnology). The precipitated complexes were washed, cross-links were reversed, and DNA fragments were amplified by PCR using oligonucleotide DNA primers that anneal to nucleotide sequences that flank conserved E-box enhancer elements within the human cyclin D2 promoter (prm primers: 5 0 -CCCCTTCCTCCTGGAGTGAAATAC-3 0 and 5 0 -CGTGCTCTAA-CGCATCCTTGAGTC-3 0 ); the control utr primers (5 0 -ATCAGACCCTATTC-TCGGCTCAGG-3 0 and 5 0 -CAGTCAGTAAGGCACTTTATTTCCCC-3 0 ) anneal to an untranslated (utr) region of the cyclin D2 gene (Awasthi et al., 2005; Vervoorts et al., 2003) . PCR products were electrophoresed through a 2% Tris-acetate-EDTA agarose gel and visualized using ethidum bromide. Dual-ChIPs were performed using HTLV-1-transformed HuT-102 lymphocytes as described in Vakoc et al. (2005) . Briefly, following the initial immunoprecipitation, nucleoprotein complexes were eluted with 10 mM DTT at 37 1C for 30 min. Samples were then diluted in ChIP-Dilution Buffer (Upstate Biotechnology) and reimmunoprecipitated using primary antibodies and 60 μl salmon sperm DNA/Protein A-agarose. The re-immunoprecipitated complexes were washed, crosslinks were reversed, and bound DNA fragments were amplified by PCR using the prm oligonucleotide primers as described (Awasthi et al., 2005) . II -GFP or a pcDNA3.1-GFP control. Transfected cultures were monitored microscopically over a two-week period until transformed colonies were visible -evidenced by the loss of contact-inhibition and pronounced cell clustering (Awasthi et al., 2005) . The plates were fixed in 70% ethanol-PBS and stained with methylene blue for improved visualization of colonies. DAPI-nuclear staining was also included in certain experiments to verify cellular foci/nuclear aggregation. The expression of HTLV-1 p30 II -GFP in transformed foci was confirmed by direct fluorescence-microscopy. Foci-formation experiments using immortalized human wrn À /À WS AG11395 fibroblasts (Moser et al., 2000) to determine the effects of dominant-negative acetyltransferase mutants, TIP60 Q377E/G380E , p300 ΔE1A , and PCAF ΔHAT (Ikura et al., 2000; Chakravarti et al., 1999; Yang et al., 1996) , upon HTLV-1 p30 To evaluate the effects of HTLV-1 p30 II and wildtype c-MYC, or acetylation-defective c-MYC K323R/K417R and R5 mutants, upon programmed cell-death induced by prolonged exposure to genotoxic stress, the co-transfected c-myc À /À HO15.19 cultures were treated with bromodeoxyuridine (BrdU) for 12 h. Subsequently, the cells were washed, fixed/permeabilized and immunostained using an antiBrdU-FITC-conjugated antibody. The DNA was stained with 7-AAD (BD-Pharmingen) and the cells were analyzed by flow cytometry (Awasthi et al., 2005) . Cytotoxicity induced by long-term BrdUexposure was observed by staining the co-transfected cultures with Annexin-V-FITC and apoptosis was quantified by direct fluorescencemicroscopy.
Foci-formation/cellular transformation
Detecting c-MYC-acetylation
To observe Lys-acetylation of the c-MYC oncoprotein, 293 HEK cells were co-transfected with CβF-CMV-c-MYC (FLAG-tagged) in the presence of increasing amounts of CMV-HTLV-1 p30 II -GFP or an empty vector control. The cells were pelleted by centrifugation at 4 1C, resuspended in RIPA buffer (phosphate-buffered saline, PBS, 1% v/v IGEPAL-CA630, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate, SDS) containing protease inhibitors (antipain dihydrochloride, bestatin, leupeptin, aprotinin, chymostatin, and pepstatin (Roche Applied Sciences)), and lysed by sonication at 70% duty cycle using a microprobe. Acetylated cellular proteins were immunoprecipitated using an anti-Acetyl-Lysine antibody (Millipore)/Protein G-agarose (Invitrogen), centrifuged and washed, resolved by SDS-PAGE, and the bound acetylated-c-MYC protein was detected by immunostaining as in Patel et al., 2004 . The status of c-MYCacetylation in HTLV-1-transformed HuT-102 and MJG11 T-lymphocytes was determined by immunoprecipitating cellular acetylated proteins using an anti-Acetyl-Lysine antibody/Protein G-agrose. As a negative IP control, immunoprecipitations were carried out in parallel using an anti-GFP antibody (Sigma-Aldrich). The acetylated-c-MYC was detected by immunoblotting as described (Patel et al., 2004) . Uninfected Jurkat E6.1 T-lymphocytes were included as a control.
BrdU-incorporation and lentiviral transductions
To determine if HTLV-1 p30 II -expressing cells enter the S-phase and replicate their genome in the presence of etoposide, HFL1 human fibroblasts (ATCC, CCL-153) were transduced with lentiviral particles expressing the HTLV-1 p30 II (HA-tagged) protein:
pLenti-6.2/V5-DEST-HTLV-1 p30 II HA, or empty pLenti-6.2/V5-DEST vector particles (Invitrogen, Inc.) as a negative control. The transduced cultures were treated with etoposide and then labeled with BrdU for 6 h. The cells were subsequently fixed, permeabilized, and stained using an anti-BrdU-FITC antibody (BD Pharmingen), and immunofluorescence-microscopy was performed to detect anti-BrdU-FITC-staining in the p30 II (HA)-expressing or vector control transduced cells.
Statistical analysis
The statistical significance and confidence intervals of experimental data sets were analyzed by determining their Student's t-distribution values (alpha ¼0.05).
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